MartinLutherKing
2 minutes ago
TransCode’s lead therapeutic candidate, TTX-MC138, is a targeted therapy designed to treat cancer patients with metastatic cancer, an area traditionally overlooked because, from a therapeutic perspective, non-metastatic and metastatic tumor cells are often viewed as being the same. However, despite
Rattlershehe
4 minutes ago
Sorry, Arnold, that was supposed to say Delisted, however, on the 10th edible gardens got the letter that they were compliant. Of course, their next big hurdle will be to go over a dollar or once again they’ll be booted off the NASDAQ. I see a reverse split in the future, but first those shares have